BofA analyst Allen Lutz notes Hims & Hers (HIMS) announced its new membership for branded Wegovy subscriptions through the recently announced NovoCare (NVO) partnership will be priced at $149 per month excluding the price of medication, which the firm calls “slightly higher than we initially expected” and modestly above peer Ro at $145 per month. The firm, which estimates Hims’ GLP-1 franchise will contract by 31% in 2026, adds that this estimate “could be optimistic as HIMS moves from a position of a low cost provider to an average cost provider of GLP-1 medications.” The firm maintains a Neutral rating on the stock.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HIMS:
- Hims & Hers announces availability of Novo Nordisk’s GLP-1 medications
- Mixed options sentiment in Hims and Hers Health with shares up 3.87%
- Hims & Hers price target raised to $25 from $17.50 at Leerink
- Hims, Novo, CrowdStrike, SolarEdge, Telus Trending With Analysts
- Morning Movers: FireFly Aerospace skyrockets following Alpha Flight 7 launch